Efficacy of indacaterol in the treatment of patients with COPD

Primary Care Respiratory Journal

Volumn 20, Issue 4, 2011, Pages 380-388

  Jones, Paul W ^a   Barnes, Neil ^b   Vogelmeier, Claus ^c   Lawrence, David ^d   Kramer, Benjamin ^e  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bronchodilators; COPD; Efficacy; Formoterol; Indacaterol; Salmeterol; Tiotropium

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL; INDACATEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EVIDENCE BASED MEDICINE; HEALTH STATUS; HUMAN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPIROMETRY; VITAL SIGN;

EID: 85027943164     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2011.00066     Document Type: Review

References (50)

1. National Clinical Guideline Centre. (2010) Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English
2. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010. At: www.goldcopd.com [accessed 22 February 2011].
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54. http://dx.doi.org/10.1056/NEJMoa0805800
4. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61(10):854-62. http://dx.doi.org/10.1136/thx.2006.063271
5. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89. http://dx.doi.org/10.1056/NEJMoa063070
6. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31(2):416-69. http://dx.doi.org/10.1183/09031936.00099306
7. Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respir Med 2008;102(2):173-88. http://dx.doi.org/10.1016/j.rmed.2007.09.011
8. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(10):948-55. http://dx.doi.org/10.1164/rccm.200906-0876OC
9. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009;103(10):1421-9. http://dx.doi.org/10.1016/j.rmed.2009.05.020
10. European Medicines Agency. Onbrez Breezhaler indacaterol. At: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001114/human_med_001219.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125. Accessed 14 February 2011.
11. Feldman G, Siler T, Prasad N, et al; INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010;10:11. http://dx.doi.org/10.1186/1471-2466-10-11
12. Donohue JF, Fogarty C, Lötvall J, et al; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182(2):155-62. http://dx.doi.org/10.1164/rccm.200910-1500OC
13. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9. http://dx.doi.org/10.1183/09031936.00045810
14. Dahl R, Chung KF, Buhl R, et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65(6):473-9. http://dx.doi.org/10.1136/thx.2009.125435
15. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2005. At: www.goldcopd.com [accessed 24 November 2010].
16. Partridge MR, Miravitlles M, Ståhl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J 2010;36(1):96-104. http://dx.doi.org/10.1183/09031936.00123709
17. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37(2):264-72. http://dx.doi.org/10.1183/09031936.00051110
18. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63(9):831-8. http://dx.doi.org/10.1136/thx.2007.086041
19. Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3(3):234-8. http://dx.doi.org/10.1513/pats.200509-103SF
20. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005-12. http://dx.doi.org/10.1056/NEJMoa021322
21. Williams M, Cafarella P, Olds T, Petkov J, Frith P. Affective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with COPD. Chest 2010;138(2):315-22. http://dx.doi.org/10.1378/chest.09-2498
22. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85(6):751-8. http://dx.doi.org/10.1378/chest.85.6.751
23. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003;56(3):248-55. http://dx.doi.org/10.1016/S0895-4356(02)00589-9
24. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21(2):267-72. http://dx.doi.org/10.1183/09031936.03.00068503a
25. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178(4):332-8. http://dx.doi.org/10.1164/rccm.200712-1869OC
26. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23(5):698-702. http://dx.doi.org/10.1183/09031936.04.00121404
27. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-38. http://dx.doi.org/10.1056/NEJMoa0909883
28. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self complete measure for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145(6):1321-7.
29. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005;2(1):75-9.
30. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56(11):880-7. http://dx.doi.org/10.1136/thorax.56.11.880
31. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19(3):398-404.
32. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio-and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105(4):571-9. http://dx.doi.org/10.1016/j.rmed.2010.11.027
33. Jones PW, Brusselle G, Dal Negro RW, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med 2011;105(1):57-66. http://dx.doi.org/10.1016/j.rmed.2010.09.004
34. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137(1):20-30. http://dx.doi.org/10.1378/chest.09-0011
35. Lee TA, Pickard S, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Int Med 2008;149(6):380-90.
36. Wood-Baker R, Cochrane B, Naughton MT. Cardiovascular mortality and morbidity in COPD: the impact of bronchodilator treatment. Intern Med J 2010;40(2):94-101. http://dx.doi.org/10.1111/j.1445-5994.2009.02109.x
37. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH Study results. Thorax 2010;65(8):719-25. http://dx.doi.org/10.1136/thx.2010.136077
38. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364(12):1093-103.
39. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143(5):317-26.
40. O'Donnell DE, Casaburi R, Vincken W, et al.; on behalf of the INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105(7):1030-6.
41. Beeh K-M, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011; in press.
42. Buhl R, Dunn LJ, Disdier C, et al.; on behalf of the INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011 May 26. [Epub ahead of print].
43. van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010;65(12):1086-91. http://dx.doi.org/10.1136/thx.2010.139113
44. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166(8):1084-91.
45. Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21(1):68-73. http://dx.doi.org/10.1183/09031936.03.00013303
46. Calverley P, Pauwels R, Vestbo J, et al; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361(9356):449-56. http://dx.doi.org/10.1016/S0140-6736(03)12459-2 Erratum in: Lancet 2003;361(9369):1660.
47. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21(1):74-81. Erratum in: Eur Respir J 2003;21(5):912. http://dx.doi.org/10.1183/09031936.03.00031402
48. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011;12(1):18. http://dx.doi.org/10.1186/1465-9921-12-18
49. EMC. DAXAS 500 micrograms film-coated tablets. Summary of product characteristics last updated on the eMC 30/07/2010. At: http://www.medicines.org.uk/EMC/medicine/23416/SPC/DAXAS [accessed 6 December 2010].
50. European Medicines Agency. Daxas roflumilast. At: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001179/human_med_001363.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125. Accessed 14 February 2011.